Skip to main
HUM

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 11%
Buy 22%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Humana's updated earnings per share (EPS) estimate for 2025 has been increased to $17.06, reflecting positive second-quarter results and revised guidance, indicating a strong financial performance outlook. Furthermore, the company's anticipated year-over-year earnings growth for 2027, alongside its initiatives for margin improvement, suggests effective operational management in the face of potential reimbursement challenges. Additionally, Humana's superior Medicare Advantage star rating profile enhances its competitive position, providing an advantage amid evolving regulatory landscapes.

Bears say

Humana's future earnings per share (EPS) are projected to decline slightly in 2026 due to headwinds from the Stars program, even though margins are expected to improve as part of management's initiatives. Significant risks impacting the company's performance include increased competition in Medicare Advantage (MA), inadequate reimbursement rates, and declining membership in the Prescription Drug Plan (PDP), all of which could exacerbate the downward trend in EPS. Additionally, management anticipates that efforts to recover the Star ratings will necessitate increased investments, potentially leading to a 10% shortfall in FY27 EPS estimates.

Humana (HUM) has been analyzed by 18 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 22% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 18 analysts, Humana (HUM) has a Hold consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $292.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $292.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.